Lunch Session Sponsored by Edwards Lifesciences

Lunch Session Sponsored by Edwards Lifesciences

Minimally-invasive treatment modalities for heart valve diseases: what is next?

  • The burden of structural heart valve diseases and learning objectives. incidence, prevalence, treatment pathways, quality of care, Francesco Maisano
  • What are current and future treatment modalities? A tailored approach.
    • My 15 years’ experience of TAVI with balloon expandable valves, John Webb
    • CENTERA: the ultimate self-expanding experience, TBD
    • Cardioband Mitral System: reducing mitral regurgitation through annular reduction, Haim Danenberg
    • Cardioband Tricuspid System: The first transcatheter device approved for treatment of tricuspid regurgitation, Ulrich Schaefer
    • Session key takeaways, Francesco Maisano